Winnow Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Winnow Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$742K	Sell	5,230 -529	-9%	-$85K	0.49%	75
2026 Q2	$971K	Sell	5,759 -191	-3%	-$28.3K	0.66%	43
2026 Q1	$784K	Sell	5,950 -312	-5%	-$41.4K	0.6%	61
2025 Q4	$889K	Sell	6,262 -548	-8%	-$79.4K	0.66%	59
2025 Q3	$960K	Buy	+6,810	New	+$923K	0.75%	55
2025 Q2	–	Sell	-6,697	Closed	-$741K	–	497
2025 Q1	$741K	Buy	6,697 +1,336	+25%	+$169K	0.68%	58
2024 Q4	$707K	Buy	+5,361	New	+$663K	0.7%	46

Other funds holding NBIX

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Winnow Wealth's NBIX Position: Q3 2026 in Review

Winnow Wealth reduced its Neurocrine Biosciences (NBIX) stake by 9.2% in Q3 2026, selling an estimated $85K and leaving 5,230 shares worth $742K. The position accounts for 0.49% of the portfolio, ranked #75.

Winnow Wealth first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $971K in Q2 2026. 143 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Winnow Wealth held 5,230 shares of Neurocrine Biosciences worth $742K as of Q3 2026.
Winnow Wealth sold 529 Neurocrine Biosciences shares in Q3 2026, an estimated $85K.
Neurocrine Biosciences made up 0.49% of Winnow Wealth's portfolio in Q3 2026, its #75 holding.
Winnow Wealth first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
Winnow Wealth's Neurocrine Biosciences position peaked at $971K in Q2 2026.
143 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Winnow Wealth's 13F filing for Q3 2026, filed 15 Oct 2026.